



# Eltroxin<sup>®</sup> tablet guide

## for Healthcare Professionals

### Current Eltroxin 100 microgram tablet\*

### NEW Eltroxin 100 microgram tablet\*



#### TABLET COMPARISON

<b>Tablet Image</b> *Tablets shown are not to actual size.	 8mm	 6.5mm
	Front  Back 	Front  Back 
Tablet Imprint	Side 1: 100 Side 2: GS21C	Side 1: 100 Side 2: L10
Tablet Shape	Round biconvex	Round, flat, beveled
Tablet Diameter	8 mm	6.5 mm

#### INGREDIENT COMPARISON

Active Ingredient	Levothyroxine sodium	Levothyroxine sodium – <i>same source as current</i>
Excipients	Microcrystalline cellulose Pregelatinised maize starch Colloidal anhydrous silica Talc Magnesium stearate	Microcrystalline cellulose Pregelatinised maize starch Colloidal anhydrous silica Talc Magnesium stearate  <b>Reduction in quantity of each excipient</b>
Allergen Advice	Sucrose, lactose and gluten free	Sucrose, lactose and gluten free

#### PRESENTATION

Packaging	<b>Bottle Only</b> 	<b>Bottle and Carton</b> 
	Pack Size	1000 tablet pack
Pharmacode	250295	2676788

Current Eltroxin  
50 microgram tablet\*

NEW Eltroxin  
50 microgram tablet\*

**TABLET COMPARISON**

<b>Tablet Image</b> *Tablets shown are not to actual size.		
	<b>Tablet Imprint</b>	Side 1: 50 Side 2: GS 11E
<b>Tablet Shape</b>	Round biconvex	Round, flat, beveled
<b>Tablet Diameter</b>	6.5 mm	6.5 mm

**INGREDIENT COMPARISON**

<b>Active Ingredient</b>	No change to active ingredient or excipients (no formulation change) Levothyroxine sodium, microcrystalline cellulose, pregelatinised maize starch, talc, colloidal anhydrous silica, magnesium stearate	
<b>Excipients</b>		
<b>Allergen Advice</b>	Sucrose, lactose and gluten free	Sucrose, lactose and gluten free

**PRESENTATION**

<b>Packaging</b>	<b>Bottle Only</b> 	<b>Bottle and Carton</b> 
<b>Pack Size</b>	1000 tablet pack	200 tablet pack
<b>Pharmacode</b>	250287	2676761

Eltroxin® (levothyroxine sodium) 50 microgram & 100 microgram tablets are a fully funded Prescription Medicine for the treatment of hypothyroidism. **Dosage & Administration:** Thyroxine has a narrow therapeutic index. Appropriate thyroxine dosage is based upon clinical assessment and laboratory monitoring of thyroid function tests. During the initial titration period, careful dosage titration and monitoring is necessary. See data sheet for dosage. Tablets should be swallowed whole preferably on an empty stomach. **Contraindications:** Hypersensitivity to any component of the product, thyrotoxicosis, acute myocardial infarction, acute myocarditis, acute pancarditis. **Adverse effects:** Hypersensitivity reactions such as skin rash, pruritis, anaphylactic reactions, increased appetite, excessive weight loss, abdominal cramps, nausea, vomiting, diarrhoea, headache, tremors, seizure, anxiety, emotional lability, nervousness, excitability, insomnia, restlessness, psychotic depression, cardiac arrhythmias, angina, palpitations, heart failure, myocardial infarction, hypertension, tachycardia, hyperthyroidism, dyspnoea, hair loss, sweating, flushing, muscle cramps, muscle weakness, decreased bone mineral density, menstrual irregularity, impaired fertility, fatigue, fever, heat intolerance. **Precautions:** Adrenal insufficiency, elderly, patients with symptoms of myocardial insufficiency/ECG evidence of myocardial infarction or ischaemia, diabetes, bone mineral density in women, partial hair loss in children during first few months of treatment, malabsorption syndromes, myxoedema, pregnancy, neonates. A number of other drugs may cause an increase or decrease in the effect of thyroxine, and the dosage of either drug may need to be altered, see data sheet for full list of interactions. Before prescribing please review data sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) Eltroxin® is a registered trademark of Aspen New Zealand, C/O Pharmacy Retailing (NZ) Ltd, Auckland. TAPS NP20570 March 2024.

